Clinical Trials
15 trialsNCT05218499 2026-03-02
Brightline-1: A Study to Compare Brigimadlin (BI 907828) With Doxorubicin in People With a Type of Cancer Called Dedifferentiated Liposarcoma
Boehringer Ingelheim
Phase 2/3 Completed
NCT06058793 2026-01-09
Brightline-4: A Study to Test How Well Brigimadlin is Tolerated by People With a Type of Cancer Called Dedifferentiated Liposarcoma
Boehringer Ingelheim
Phase 3 Completed
NCT02451943 2025-07-15
ANNOUNCE
Eli Lilly and Company
Phase 3 Completed
NCT06115681 2025-07-10
Real-world Study of Dedifferentiated Liposarcoma Patients in China
Boehringer Ingelheim
Completed
NCT04028479 2024-12-18
ROOT
Taproot Health
Completed
NCT02606461 2023-01-23
SEAL
Karyopharm Therapeutics Inc
Phase 2/3 Completed
NCT02343172 2020-12-09
Study of Safety and Efficacy of HDM201 in Combination With LEE011 in Patients With Liposarcoma
Novartis
Phase 1 Completed
NCT01692678 2018-07-11
A Study of Trabectedin (YONDELIS) in Patients With Locally Advanced or Metastatic Liposarcoma or Leiomyosarcoma
Xian-Janssen Pharmaceutical Ltd.
Phase 3 Completed
NCT00154388 2016-11-18
Phase II Study of Imatinib Mesylate in Patients With Life Threatening Malignant Rare Diseases
Novartis
Phase 2 Completed
NCT00413075 2015-07-08
Study of Oral PXD101 in Patients With Advanced Solid Tumors or Lymphoma
Valerio Therapeutics
Phase 1 Completed
NCT00413322 2015-07-08
Study of PXD101 Alone and in Combination With 5-Fluorouracil (5-FU) in Patients With Advanced Solid Tumors
Valerio Therapeutics
Phase 1 Completed
NCT00093080 2015-02-13
Study of AP23573/MK-8669 (Ridaforolimus), A Mammalian Target of Rapamycin (mTOR) Inhibitor, in Participants With Advanced Sarcoma (MK-8669-018 AM1)(COMPLETED)
Merck Sharp & Dohme LLC
Phase 2 Completed
NCT00060944 2014-09-08
A Study to Assess Treatment With 2 Different Dosing Schedules of Trabectidin Administered to Patients With Advanced Cancer
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Phase 2 Completed
NCT00579501 2014-05-07
Safety and Efficacy Study of Trabectedin for the Treatment of Localized Myxoid / Round Cell Liposarcoma
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Phase 2 Completed
NCT00064220 2012-05-16
Soblidotin in Treating Patients With Advanced or Metastatic Soft Tissue Sarcoma
Daiichi Sankyo
Phase 2 Completed